{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Diaz-Garcia J"],"funding":["EC | European Regional Development Fund (ERDF)","MEC | Instituto de Salud Carlos III (ISCIII)"],"pagination":["e0098623"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10783443"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["67(11)"],"pubmed_abstract":["We previously conducted a multicenter surveillance study on <i>Candida</i> epidemiology and antifungal resistance in Madrid (CANDIMAD study; 2019-2021), detecting an increase in fluconazole-resistant <i>Candida parapsilosis</i>. We here present data on isolates collected in 2022. Furthermore, we report the epidemiology and antifungal resistance trends during the entire period, including an analysis per ward of admission. <i>Candida</i> spp. incident isolates from blood cultures and intra-abdominal samples from patients cared for at 16 hospitals in Madrid, Spain, were tested with the EUCAST E.Def 7.3.2 method against amphotericin B, azoles, micafungin, anidulafungin, and ibrexafungerp and were molecularly characterized. In 2022, we collected 766 <i>Candida</i> sp. isolates (686 patients; bl"],"journal":["Antimicrobial agents and chemotherapy"],"pubmed_title":["Trends in antifungal resistance in <i>Candida</i> from a multicenter study conducted in Madrid (CANDIMAD study): fluconazole-resistant <i>C. parapsilosis</i> spreading has gained traction in 2022."],"pmcid":["PMC10783443"],"funding_grant_id":["PI19/00074","PI18/01155"],"pubmed_authors":["Perez-Ayala A","CANDIMAD study group","Garcia-Esteban C","Sanchez-Garcia A","Sanchez-Carrillo C","Diaz-Garcia J","Alcala L","Zurita ND","Machado M","Gomez A","San Juan-Delgado F","Reigadas E","Gomez-Garcia de la Pedrosa E","Cuetara MS","Munoz-Algarra M","Quiles-Melero I","Bernal G","Perez-Munoz R","Duran-Valle MT","Vera-Gonzalez MDC","Gil-Romero Y","Sanchez-Romero I","Cuevas-Lobato O","Munoz P","Escribano P","Guinea J","Gomez-Garcia De La Pedrosa E","Mesquida A","Fraile Torres AM","Merino-Amador P","Gutierrez-Cobos A","Gonzalez-Romo F"],"additional_accession":[]},"is_claimable":false,"name":"Trends in antifungal resistance in <i>Candida</i> from a multicenter study conducted in Madrid (CANDIMAD study): fluconazole-resistant <i>C. parapsilosis</i> spreading has gained traction in 2022.","description":"We previously conducted a multicenter surveillance study on <i>Candida</i> epidemiology and antifungal resistance in Madrid (CANDIMAD study; 2019-2021), detecting an increase in fluconazole-resistant <i>Candida parapsilosis</i>. We here present data on isolates collected in 2022. Furthermore, we report the epidemiology and antifungal resistance trends during the entire period, including an analysis per ward of admission. <i>Candida</i> spp. incident isolates from blood cultures and intra-abdominal samples from patients cared for at 16 hospitals in Madrid, Spain, were tested with the EUCAST E.Def 7.3.2 method against amphotericin B, azoles, micafungin, anidulafungin, and ibrexafungerp and were molecularly characterized. In 2022, we collected 766 <i>Candida</i> sp. isolates (686 patients; bl","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Nov","modification":"2025-05-29T20:27:16.608Z","creation":"2025-05-29T20:27:16.608Z"},"accession":"S-EPMC10783443","cross_references":{"pubmed":["38092562"],"doi":["10.1128/aac.00986-23"]}}